The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q).

ABSTRACT:

Introduction

The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia.

Methods

CIMA-Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community.

Results

In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well

SUBMITTER: Belleville S 

PROVIDER: S-EPMC6880140 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature